A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3

Jenni Lahtela,1 Laura B. Corson,2 Annabrita Hemmes,1 Matthew J. Brauer,2 Sonja Koopal,1 James Lee,2 Thomas L. Hunsaker,2 Peter K. Jackson2,‡ and Emmy W. Verschuren1,*,†

1Institute for Molecular Medicine Finland (FIMM); University of Helsinki; Helsinki, Finland; 2Genentech Inc.; South San Francisco, CA USA

†These authors share co-senior authorship.

Keywords: senescence, DDR, p53, p16INK4a, tumor suppressor, EPHA3, RTK

Abbreviations: DDR, DNA damage response; SA-β-Gal, senescence associated-β-galactosidase; CGH, comparative genomic hybridization; EPHA3, EPH receptor A3; RTK, receptor tyrosine kinase

Introduction

Cancer genomic profiling studies have revealed that the majority of drivers for malignant tumor progression are mutations in tumor suppressors,1,2 illustrating the need to accurately catalog cancer-specific tumor suppressors and their impact on treatment efficacy. Reverse genomics approaches using RNA interference (RNAi) libraries allow for rapid identification of novel gene functions and ideally, monitor cellular parameters tightly linked to the function in question. Common to many potent oncogenic signals is the activation of built-in checkpoint mechanisms that halt aberrant proliferation, instead triggering irreversible cellular fates, including apoptosis and senescence.3 It is well-established that senescence can result not only from prolonged oncogene activation (e.g., oncogenic Ras, cyclin E), but also loss of tumor suppression (e.g., loss of PTEN, VHL or NF1 genes).4 A physiological role for senescence in suppressing malignant progression is supported by its in vivo detection during early stages cancer development.5,6

The program of cellular senescence comprises permanent cell cycle arrest associated with cellular morphological changes, notably cell and nuclear flattening and an increase in senescence-associated β-galactosidase (SA-β-Gal) activity.7 Senescence in vitro and in vivo coincides with the occurrence of ATM/ATR and p53/p21Cip1 DNA damage response (DDR) pathways, and previous research, including our own, suggests this to be a consequence of unbalanced DNA replication vs. mitotic cell cycle stages.8-10 Senescence is also commonly triggered by activation of the Ets/p16INK4a/Rb tumor suppressor pathway. Although the role of DDR and p16INK4a pathways in mediating senescence is well established, their relative contributions remain ill-defined and multiple pathways may act cooperatively.4

Since senescence is commonly detected in cells containing intact cellular DDR and p16INK4a pathways, we reasoned that a siRNA screen in untransformed cells would potentially identify putative tumor suppressor genes. Our screen contrasts with previous studies, which focused on senescence bypass events, and biased for discovery of genes intrinsically linked to or required for the specific arrest pathway.11-13 Furthermore, the proposed pro-tumorigenic effect of a senescence-associated inflammatory response14 warrants a closer study to assess whether senescence can
be induced upon loss of relevant gene function. Here we identify 12 kinases as newly identified regulators of cellular senescence using quantitative senescence β-galactosidase staining, and show that senescence frequently correlates with DNA damage induction and is mostly p53- and sometimes p16\(^{INK4A}\)-dependent. In support of our hypothesis to reveal candidate tumor suppressor genes, analysis of SNP aCGH data showed that a significant number of candidate genes displayed gene copy loss in sets of tumor samples.

Interestingly, one novel senescence regulator, the \(\text{EPHA3}\) receptor tyrosine kinase (RTK) gene, is among the most frequently mutated genes in human lung adenocarcinomas and colorectal cancers.\(^{15,16}\) \(\text{EPHA}\) receptors have traditionally been assigned oncogenic roles due to their overexpression in a variety of cancers including carcinomas, melanoma and gliomas.\(^{19,20}\) However, in support of additional tumor suppressor functions, certain ephrin-EPHs are suggested to show temporally bi-phasic roles during tumor progression,\(^{21}\) and \(\text{EPHA7}\) receptor was recently shown to act as a tumor suppressor in follicular lymphoma.\(^{22}\) We here show that senescence upon loss of \(\text{EPHA3}\) is regulated by \(\text{p16}^{INK4a}\) and p53 and, in agreement with recent data from the Pasquale and Zhuang labs,\(^{23,24}\) show that selected \(\text{EPHA3}\) tumor-associated mutations decrease receptor expression levels and overall kinase activity. Our results suggest that concomitant loss of \(\text{EPHA3}\) and key senescence-inducing tumor suppressor functions may cooperatively stimulate tumorigenesis, and conclude that our senescence screen successfully identified strong candidates for tumor suppressor genes.

**Results**

**Identification of senescence-inducing kinase siRNAs.** We utilized a cell-based screen to identify regulators of premature senescence in untransformed cells, hypothesizing that a loss-of-function screen may identify new tumor suppressor genes. We chose to screen the \(\text{hTERT}^{-}\)-immortalized retinal pigmented epithelial line \(\text{hTERT-RPE1}\), because it models key aspects of untransformed cells, including quiescence with a high efficiency of \(G_0\) markers, notably the presence of primary cilia.\(^{25}\) Unlike quiescent cells, senescent cells exhibit an irreversible proliferative arrest, followed by formation of enlarged nuclei and a flattened cytoplasmic morphology, with rare exceptions.\(^{8}\) These features were used to analyze a multiparametric HCS siRNA screen of \(\text{hTERT-RPE1}\) cells engineered to express a doxycycline-inducible \(\text{p53}\) shRNA (from here on called \(\text{hTERT-RPE1 p53shRNA}\), designed to identify proteins that impinge on the \(\text{p53}\) pathway (Corson LB, et al., manuscript in preparation). Our analysis focused on loss of the proliferation marker Ki67 and decreased nuclei counts, combined with an average increase in nuclear size (Fig. 1A). This approach identified a group of 16 kinase siRNAs, which we labeled as “senescence-like” (Fig. 1B).

We next tested hits as bona fide senescence regulators in a secondary screen detecting the widely studied SA-β-Gal senescence biomarker, on parallel transfections using siRNA pools plus the four individual siRNAs per gene. Knockdown of \(\text{Emil}\), previously reported to elicit pronounced DNA damage-induced senescence in \(\text{hTERT-RPE1}\) cells, was included as a positive control\(^4\) (Fig. S1A). Normalized senescence scores were calculated by quantitation of the staining intensities per single oligonucleotide pool (Fig. S1B and Table S2). To correlate the phenotype with knockdown efficiency, we performed TaqMan RNA expression analysis (Fig. S2). Genuine hits were assigned if both the siRNA pool, plus at least two oligonucleotides conferring > 50% knockdown efficiency, scored positive (Table S3). This approach validated 12 of 16 senescence-like kinase siRNAs as genuine senescence hits (Fig. 1C).

**Delineation of senescence signatures.** Activation of a p53-dependent DNA damage response (DDR) and increased \(\text{p16}^{INK4a}\) CKI expression have been causally linked to senescence. \(\text{hTERT-RPE1}\) cells contain an intact p53 checkpoint, and p53 stabilization and nuclear accumulation are seen upon sustained damage signaling.\(^{8,26}\) A two- to 4-fold increase in cells expressing threshold p53 and p21\(^{CIP1}\) protein levels was measured in the HCS analysis (Fig. 2A). In all cases, total cell numbers and percentages of proliferating cells were significantly increased in \(\text{p53}\) knockdown cells compared with \(\text{p53}^+\) cells (Fig. 2B; Fig. S3A), suggesting a p53-dependent growth arrest. Furthermore, we measured increased DNA damage by γ-H2AX foci formation upon senescence induction in all but one case (PIK3C2A), with strongest hits showing foci in 40–50% of cells (Fig. S3B). Finally, a decreased senescence score was measured after transfection of six of 12 senescence hit siRNAs in \(\text{p53}\) knockdown cells (Fig. 2C), implying that senescence typically required activation of a p53-dependent DDR.

Next, we assessed activation of the \(\text{p16}^{INK4a}\) tumor suppressor pathway following senescence suppressor siRNA transfection. In \(\text{hTERT-RPE1}\) cells, classic senescence induction following oncogenic RAS expression did not result in a significant increase in \(\text{p16}^{INK4a}\) mRNA (data not shown). Contrary to p53 pathway activation, significant increases in \(\text{p16}^{INK4a}\) mRNA expression were less frequently detected upon senescence hit siRNA transfection, and most clearly upon knockdown of \(\text{MYLK, MAP2K3, NEK1, EPHA3 and SMG1}\) (Fig. 2D). We conclude that in a majority of cases senescence induction is associated with activation of well-known cell cycle arrest pathways, schematically summarized in Figure 2E. As expected, this corresponds to a delayed cell cycle progression, as measured by DNA replication analysis in synchronized cells (Fig. S4).

**Genome copy number and mutational analysis to appoint putative tumor suppressors.** To establish whether senescence hits encompass tumor suppressors, we combined a cancer genomic analysis approach with cancer mutation and literature surveys. Validating our hypothesis, three hits identified have previously been shown to display bona fide tumor suppressor functions in murine models (Fig. 1C). Specifically, \(\text{AurkA}\) heterozygous mice present haploinsufficient tumor suppression with increased incidence of lymphoma, lung and liver tumors;\(^{27}\) conditional \(\text{Cnk1tal}\) ablation triggers colorectal carcinogenesis and LOH;\(^{28}\) and \(\text{Lat1}\)-deficient mice develop soft tissue sarcoma and ovarian tumors.\(^{29}\) Interestingly, all three models exhibit signs of chromosomal instability or DDR activation, and a p53-dependent DDR-senescence response is proposed to halt carcinogenesis in the \(\text{Cnk1tal}-\text{null}\) or heterozygous animals.\(^{28}\) This verifies that
individual findings from our in vitro study have a capacity to broaden our knowledge of physiological disease progression.

Among the candidates, only \textit{LATS1} is suggested to act as a tumor suppressor in human disease, supported by its conserved role in growth control from flies to man\textsuperscript{15} (Fig. 1C). We therefore next asked if we could observe an increased propensity for genome copy number loss of our senescence genes in human tumor samples. Validating our strategy, loci encompassing known tumor suppressors showed significant copy number loss across data sets, defining a “tumor suppressor copy number signature.” Importantly, clustering analysis of this signature identified a set of five screen candidates with a similar genomic profile, namely \textit{LATS1}, \textit{CDK1}, \textit{EPHA3}, \textit{NEK1} and \textit{MAP2K3} (Fig. 3). Locus inspection showed none to be in the vicinity of known tumor suppressors, supporting the deduction that these constitute candidate tumor suppressor genes.

As a final in silico approach, we surveyed the increasing collection of cancer-specific mutations as reported in the COSMIC database. Indeed, out of the 12 genes, seven genes were mutated in 1–4% of tumors. Of outstanding interest, with a reported mutation frequency of 4–6%, the \textit{EPHA3} gene was shown to be among the most frequently mutated genes in human colorectal, lung and ovarian carcinomas.\textsuperscript{15-18,31} Furthermore, \textit{EPHA} RTK family kinases have pleiotropic functions and \textit{EPHA3} was originally assigned oncogenic properties in lymphomas.\textsuperscript{21,32} We thus decided to key in on a putative new role for \textit{EPHA3} as a tumor suppressor.

Loss of \textit{EPHA3} receptor signaling confers \textit{p16\textsubscript{INK4A}} and \textit{p53}-dependent senescence. Since the \textit{EPHA} RTK family consists of nine members, we first asked if \textit{EPHA3} uniquely induced cellular senescence using SA-\textgamma-Gal staining upon siRNA transfection of additional \textit{EPHA} receptors expressed in hTERT-RPE1 (\textit{EPHA1, A2, A4, and A5} mRNAs, data not shown). Knockdown of \textit{Emi1} was included as a positive control.\textsuperscript{8} Our results showed that senescence was uniquely detected after knockdown of \textit{EPHA3} and not measurably apparent after knockdown of other \textit{EPHA} RTKs expressed in hTERT-RPE1 cells (Fig. S5).
Characterization of the senescence signature showed that siRNA-mediated knockdown of EPHA3 leads to increased p16INK4a and p53 expression (Fig. 2A and D). We next asked if the senescence phenotype was mediated by p16INK4a or p53 activation using in vivo imaging. Time-lapse imaging of siRNA-treated hTERT-RPE1 cells stably expressing GFP-tagged H2B protein showed a rescue of EPHA3 knockdown-induced senescence when p16INK4a (Fig. 4A; Fig. S5E) or p53 (Fig. 4B; Fig. S5F) were co-depleted. A rescue of senescence was both measured by an increase in total cell number, as well as a decrease in average nuclear size. We therefore conclude that EPHA3 knockdown-induced senescence requires p16INK4a and p53.

Selected EPHA3 gene mutations confer loss of kinase function. Similar to other EPHA RTKs, activation of EPHA3 occurs via autophosphorylation of conserved tyrosine residues and ephrin ligand binding triggers receptor oligomerization and consequent receptor activation.34 To find how tumor-associated EPHA3 point mutations affect receptor activity we assayed for kinase activity monitoring autophosphorylation. HEK 293T and hTERT-RPE1 cells expressing a select set of EPHA3-LAP

![Image of the document content]

Figure 2. Delineation of senescence signatures. (A) hTERT-RPE1 p53 shRNA cells were transfected with kinome siRNAs in the absence of doxycycline and immunostained for p53 and p21 in vitro following 72 h culture. Percentages of cells expressing p53, p21 in vitro, above threshold levels were calculated, and averages from four 384 wells are shown. (B) hTERT-RPE1 p53 shRNA cells were transfected with kinome siRNAs in the absence or presence of doxycycline and immunostained for Ki67. Percentages of cells expressing Ki67 protein above threshold levels were calculated, and averages from four 384 wells are shown. * indicates p ≤ 0.05 and ** indicates p ≤ 0.01. (C) Senescence scores per gene are the sum of the senescence scores of the siRNA pool plus four individual siRNAs, omitting siRNAs conferring less than 50% knockdown. Detailed scoring information is depicted in Table S3. (D) Quantitative p16INK4a mRNA expression analyses during senescence induction. hTERT-RPE1 p53 shRNA cells were transfected with pooled siRNAs in the absence of doxycycline. RNA expression was quantitated using TaqMan analyses after 3 days of transfection. (E) Schematic model summarizing kinase screen data, using data depicted in (A) and (D). In an incipient tumor, modeled by hTERT-RPE1 cells, loss of selected tumor suppressors activates p53- and/or p16INK4a-dependent senescence, and overt DNA damage. In a premalignant tumor, senescence may serve as a cell-intrinsic tumor suppressor mechanism to subvert oncogenic transformation. Loss of p16INK4a and/or p53 promotes malignancy.
tumor-associated mutation variants were generated to assess relative cellular receptor activities (Fig. 5A; Fig. S6A and B). As expected, ephrin-A5 ligand activation leads to receptor internalisation and trafficking via the early endosomal compartment labeled with EEA1 (Fig. S7). Of note, a decreased steady-state expression of the R728L variant was detected in both cell lines, and the T933M variant in hTERT-RPE1 cells (Fig. S6A and B). Wild type EPHA3 shows a transient activation curve following ephrin-A5 ligand-induced activation, peaking at 20 min (Fig. 5B), consistent with published data. Decreased normalized cellular kinase activities were detected for two receptor variants mutated in the cytoplasmic region (G766E and D806N) and one variant mutated in the cytoplasmic region showed a decrease in overall receptor level (R728L) (Fig. 5B). We next asked how point mutations affected absolute kinase activity using in vitro immunoprecipitation kinase assays. In this assay, EPHA3 variants G766E and D806N showed a clear loss of kinase activity (Fig. 5C; Fig. S6C). We conclude that selected intracellular EPHA3 tumor-associated point mutations lead to a decrease in receptor expression level and/or normalized tyrosine kinase activity.

Structural analysis of EPHA3 kinase domain cancer point mutations. Next, we examined the crystal structure of the juxtamembrane and kinase domain (JMKIN) of wild type EPHA3 to explain possible functional deficiencies of the tumor-associated mutations. The mutated residues K761, G766 and D806 are situated within the kinase domain, while R728 is situated on the surface area between two α-helices (Fig. S6D). We were unable to assess the G766 variant as the crystal structure surrounding this residue is disordered. Arginine 728 to Leucine alteration causes a shift in the surface charge from positive to non-charged (Fig. 5D), which may affect the steady-state expression level of the receptor via altered protein-protein interactions and/or increased receptor degradation, explaining its reduced expression level (Fig. 5B; Fig. S6A and B). Mutation of residue 806 from aspartic acid to asparagine may alter the interaction between residues aspartic acid 746 and histidine 744, which face the ATP binding pocket and may therefore directly affect the EPHA3 catalytic activity (Fig. 5E).

Interestingly, structural alignment of EPHA3 JMKIN with the tumor suppressor LKB1 kinase domain showed that LKB1 lung cancer-associated point mutation D237Y is homologous to mutated residue D806 in EPHA3. We therefore tested EPHA3 D806Y mutation for kinase activity, and show that this mutant is kinase-defective (Fig. 5F and G). We conclude that selected cancer-associated point mutations appear to affect EPHA3 kinase activity either through altering protein-protein interactions, or through direct effects on kinase domain structural determinants, decreasing EPHA3 receptor tyrosine kinase activity. This supports our hypothesis that EPHA3 acts as a tumor suppressor gene.

Discussion

Cancer genomics initiatives have identified numerous often low-frequency mutations that can prove predictive for clinical response to targeted therapy, creating new opportunities for personalized cancer care and biomarker discovery. Not surprisingly, clinical response and therapy resistance can be critically modified by the...
landscape of tumor suppressor mutations,\textsuperscript{36} which constitute in fact the majority of cancer drivers.\textsuperscript{1} Yet, the detailed consequences of tumor suppressor mutations are often unknown. We developed a “bottom-up” senescence-based strategy to functionally identify tumor suppressor candidates. Validating our approach, we identified three genes with known tumor suppressor function in human or mouse (\textit{AURKA}, \textit{CSNK1A1} and \textit{LATS1}), and SNP aCGH data showed that half of the candidates displayed increased genome copy loss in tumor sample sets (Fig. 3). Clearly, our study is not exhaustive and would be enhanced by parallel assessment of DNA methylation and gene expression changes. Nonetheless, it illustrates the power of combining functional genomics with delineation of somatic mutations. We propose that detection of senescence in cells harbouring intact damage checkpoint pathways, such as hTERT-RPE1, can be employed as a shortcut to identify cancer-promoting events.

Our senescence gene hits can readily be grouped in three functional categories: (1) regulators of accurate mitotic cell cycle progression and cytokinesis, DNA damage signaling and the spindle assembly checkpoint (SAC): AURKA, CDK1, CSNK1A1, LATS1, NEK1, SMG1; (2) regulators of adhesion and migration: EPHA3, MYLK, PIK3C2A; and (3) regulators of growth factor-induced mitogenic signaling via p38 SAPK and JNK: KSR2, MAP2K3, MAP4K1. Hence, a compendium of genes that intersect on accurate spindle assembly checkpoint control and fine-tuning of cell adhesion as well as cytokinesis machineries describe a likely set of candidate tumor suppressors. This is further supported by recent sequencing efforts that reveal frequent mutations in mitotic kinases including Aurora, Polo and LATS kinases as well as Nek family kinases.\textsuperscript{17,37} Although conceptually perhaps unsurprising, functional data mining also reveals unexpected dual functions for previously established oncogenic proteins, as exemplified by the \textit{AURKA} oncogene, which indeed was shown to be haploinsufficient for tumor suppression in mice.\textsuperscript{27}

Senescence can be viewed as a cell-intrinsic fail-safe response to overt oncogenic proliferative signals,\textsuperscript{3} a key effector of cancer

\textbf{Figure 4.\hspace{1em}Loss of EPHA3 confers p16\textsuperscript{INK4a}- and p53-dependent senescence.} Live cell analysis of (A) EPHA3 plus p16\textsuperscript{INK4a} siRNA-treated and (B) EPHA3 plus p53 siRNA-treated hTERT-RPE1 cells. The average nuclear area of all cells per image is shown. Representative 20× images from each condition are shown in the lower panels.
previous studies describing p53 activation and/or senescence upon loss or inhibition of AURKA, CDK1, CSNK1A1, LATS1, MAP2K3, and SMG1. This further illustrates the importance of perturbations in both surveillance systems and checkpoint response pathways as a frequent driver of tumor progression.

Contrary to p53 activation, significant increases in p16 INK4a mRNA expression were less frequently detected upon senescence hit siRNA transfection, and most clearly upon loss of MYLK, MAP2K3, SMG1, NEK1 and EPHA3 (Fig. 2D). None of these genes were previously known to activate the p16 INK4A-dependent senescence program. Of the candidate tumor suppressors, the EPHA3 RTK gene was shown to be frequently mutated in human chemotherapy response, or a barrier to tumor initiation in incipient human tumors. Contrary to such anti-proliferative responses, senescence in the stromal microenvironment may also promote paracrine epithelial tumor growth via secretion of inflammatory molecules, akin to a tissue repair response. Furthermore, an elegant recent study suggested that inflammatory signals themselves can subvert a senescence barrier. Its precise physiological role thus is likely complex and possibly context-dependent, yet common to a multi-step carcinogenesis paradigm wherein loss of p53 and/or p16INK4a affords proliferation of damaged cells. We confirm that senescence correlates with activation of a pronounced p53-dependent DDR, consistent with previous studies describing p53 activation and/or senescence upon loss or inhibition of AURKA, CDK1, CSNK1A1, LATS1, MAP2K3, and SMG1. This further illustrates the importance of perturbations in both surveillance systems and checkpoint response pathways as a frequent driver of tumor progression.

Contrary to p53 activation, significant increases in p16INK4a mRNA expression were less frequently detected upon senescence hit siRNA transfection, and most clearly upon loss of MYLK, MAP2K3, SMG1, NEK1 and EPHA3 (Fig. 2D). None of these genes were previously known to activate the p16INK4A-dependent senescence program. Of the candidate tumor suppressors, the EPHA3 RTK gene was shown to be frequently mutated in human
lungs adenocarcinomas and colorectal cancers. Consistent with its candidacy as a tumor suppressor, array CGH data showed frequent loss of the chromosome 3 arm encoding EPHA3 in the lung cancer dataset in particular. This is confirmed by recent data reporting a striking loss of the EPHA3 gene in 42% of primary lung adenocarcinomas. We found that senescence upon EPHA3 loss is partially rescued by concomitant p16INK4a or p53 depletion, and that this is a function unique to EPHA3. Our data therefore suggests that loss of EPHA3 activity may promote tumorigenesis only when key senescence-inducing tumor suppressor pathways are absent. We however did not detect an enrichment for p16INK4a mutations in lung cancer samples that display EPHA3 copy number loss, using the CONAN CGP copy number analysis tool available via the Sanger Institute. The in vivo functional cooperation of EPHA3 and p16INK4a loss of function is, however, unlikely straightforward and uniform, warranting closer inspection of their co-dependencies during tumorigenesis.

Previous EPH receptor studies have revealed dual opposing roles during tumor initiation vs progression, and EPHA3 has been ascribed both oncogenic and tumor-suppressive functions. In support of its role as a tumor suppressor, EPHA3 gene loss is partially rescued by concomitant p16INK4a or p53 depletion, evidence for negative regulation of c-MET by EPHA signaling. Interestingly, a secreted form of EPHA7 was recently shown to cooperate with other EPH receptors in a dominant-negative fashion. Since also EPHA2 is phosphorylated on tyrosine 728, a mutation analogous to D237Y in the well-established LKB1 tumor suppressor, it is well-established that the interplay between different EPH receptor tyrosine kinase signaling networks is highly complex and can have both positive and negative effects on cancer cell growth. It is possible that EPHA3 and EPHA2 may functionally compensate for each other in vivo.

Materials and Methods

Cell lines, culture and treatment. hTERT-RPE1 cells (Clontech) were maintained in DMEM:F-12 (Invitrogen) containing 10% FBS, 2 mM L-Glutamine, and 0.348% sodium bicarbonate, following manufacturer recommendations. 293T cells were maintained in DMEM (Lonza) containing 10% FBS and 2 mM L-Glutamine, following manufacturer recommendations. Inducible p53 shRNA hTERT-RPE1 cells were constructed using the pHUSH tetracycline-inducible retrovirus gene transfer vector with a previously described p53 shRNA and labeled hTERT-RPE1 p53 shRNA. Knockdown in the selected subclone was validated by absence of p53 and p21 induction upon etoposide treatment, and p53 protein was absent after 72h treatment with 1 μg/ml doxycycline. A stable H2B-GFP hTERT-RPE1 clonal cell line was generated by transfection with GFP-tagged human H2B plasmid (pEGFP-H2B-N1) followed by clonal selection using G418 (Roche). High-content kinase siRNA screen. hTERT-RPE1 p53 shRNA cells were treated +− 1 μg/ml doxycycline for three days prior to transfection, also called “p53+” or “p53−” cells. A Dharmacon siGENOME library, composed of 862 siRNA pools targeting kinases and proteins predicted to influence kinase signaling was used (Table S1; Corson et al. manuscript in preparation). Following three days of culture, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100 and blocked in 5% fish gelatin (Sigma). Cells were immunostained with primary antibodies in 5% fish gelatin during overnight incubation at 4°C and incubated with secondary antibodies for 1 h at ambient temperature. Primary antibodies were rabbit anti-p53 (Cell Signaling 928; 1:1,500), goat anti-p21 (R&D Systems AF1047; 1:20,000) and mouse-anti-Ki67 (BD PharMingen 55600; 1:1,500). Secondary antibodies were Cy3 anti-rabbit (Jackson 715-495-152), Cy3 anti-goat (Invitrogen A11055). Hoechst 33342 was used at 1:50,000. For primary screen data analysis depicted in Figure 1B, the data set in which p53 was functional (p53+) was used.

HCS imaging, quantitation and statistics. 384 Multiwell plates were imaged with a 10x objective and 2 x binning on the ImageXpress Micro high content imaging system (Molecular Devices). Four sites were acquired per well with duplicate wells for every condition. Analysis using MetaXpress Cell Scoring and Multiwavelength Modules included: (1) total number of nuclei; (2) percentage cells positive for p53, p21 and Ki67; and (3) average nuclear size. An image analysis example is shown in the Supplementary Materials and Methods.
SNP array-CGH tumor sample analysis. SNP/CHIP array-CGH data available at Genentech (CARFOG, June 2009) for 2654 samples from 53 human tumor and cell line panels was mined using the "genoset" package from Bioconductor57 and plotted as a heatmap to show the fraction of samples per data set containing a genome locus copy number lower than 1.5 copies. For visualization, the scale was trimmed at a value of 0.3; data sets with this value or greater were shown with the maximum density of the scale.

Immunoprecipitation and western blotting. Cells expressing stable LAP-tagged EPHA3 proteins were serum starved for 1 h, and then incubation with 1.5 μg/ml recombinant human ephrin-A5-Fc or IgGl-Fc proteins (R&D Systems) pre-clustered for 20 min with anti-human Fc antibody (Jackson ImmunoResearch) at 10:1 molar ratio. Ligand-activated 293T cells expressing LAP-tagged EPHA3 proteins were lysed in RIPA buffer containing Protein Inhibitor Cocktail (Roche) and Phosphatase Inhibitor Cocktail (Roche). 500 μg of protein was rotated for 16h with 1 μg of anti-GFP antibody (Invitrogen). Antigen was captured using Protein G/A Sepharose beads (Sigma). Alternatively, specific antigen was captured using S-protein agarose beads (Novagen). Samples were immunoblotted using anti-phosphotyrosine (PY 4G10; Upstate Biotechnology Inc.) or in-house affinity-purified anti-GFP antibodies.

In vitro kinase assay. 293T and hTERT-RPE1 cells expressing LAP-tagged EPHA3 proteins were lysed in RIPA buffer containing protease inhibitors. 500 μg of total protein was incubated for 1h with 1 μg of antibodies to GFP (Invitrogen). Specific antigen was captured using Protein A/G Sepharose beads (Thermo Scientific), or, alternatively, with S-protein agarose beads (Novagen), and washed using RIPA and kinase buffer (50 mM NaCl, 20 mM Hepes pH 7.2, 10 mM MgCl2, 2 mM EDTA, 0.02% Triton X-100). Beads were next incubated in kinase buffer supplemented with 20 μM Adenosine 5’-triphosphate disodium salt hydrate (Sigma). Samples were immunoblotting using anti-phosphotyrosine or anti-GFP antibodies.

Live cell imaging. hTERT-RPE1 cells expressing H2B-GFP protein were treated with 50 nM pooled siRNA using forward transfection with Oligofectamine reagent (Invitrogen) on 24-well plates. Transfections were in replicates of four and imaging was performed using the IncuCyte™ FLR instrument (Essen BioScience) for five days. A duplicate plate was harvested at day three to confirm siRNA knockdown. IncuCyte object analysis was performed with default parameters.

Disclosure of Potential Conflicts of Interest

The authors disclose no potential conflicts of interest.

Acknowledgments

We wish to acknowledge Alex Loktev, Mindan Sfakianos, Chris Westlake, David Davis and Seija Hackl for providing expert advice and technical support. We are grateful to Meredith Sagolla and Jeff Eastham-Anderson for advanced light microscopy support, Denis Kainov for structural analysis support and thank members of the Jackson and Verschuren labs for discussions. pEGFP-H2B-N1 was a gift from Jorge Torres (UCLA).

Author Contributions

J.L., L.B.C., A.H., S.K., T.L.H. and E.W.V. conducted aspects of the experimental design, performed experiments, and data interpretation. James L. managed the siRNA library and M.J.B. performed statistical data analysis. P.K.J., L.B.C., J.L. and E.W.V. interpreted results, and J.L. and E.W.V. wrote the manuscript.

Financial Disclosures

Research was supported by an EU-FP7 Marie Curie Grant PIRG06-GA-2009-256485 (E.W.V.), the Sigrid Juselius and Orion-Farmos Foundations (E.W.V.), and a Graduate Program scholarship to J.L.

Supplemental Materials

Supplemental materials may be found here: www.landesbioscience.com/journals/cc/article/23515

References

1. Bozic I, Antal T, Ohlsouki H, Carter H, Kim D, Chen S, et al. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A 2010; 107:18545-50; PMID:20876136; http://dx.doi.org/10.1073/pnas.1010978107
2. Forber SA, Bindal N, Bamford S, Cole C, Kulk CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue):D945-50; PMID:20952405; http://dx.doi.org/10.1093/nar/gkq929
3. Lowe SW, Cepko E, Evan G. Intrinsic tumor supression. Nature 2002; 415:37-44; PMID:12090902; http://dx.doi.org/10.1038/nature003098
4. Kuhlman T, Michaloglou C, Mooi WP, Peper DS. The essence of senescence. Genes Dev 2010; 24:2463-79; PMID:21078816; http://dx.doi.org/10.1101/gad.1971601
5. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 2010; 10:51-7; PMID:20029423; http://dx.doi.org/10.1038/nrc2772
6. Ohtani N, Mann DJ, Harai E. Cellular senescence: its role in tumor suppression and aging. Cancer Sci 2009; 100:792-7; PMID:19302284; http://dx.doi.org/10.1111/j.1349-7006.2009.01123.x
7. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Rockelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363-7; PMID:7568133; http://dx.doi.org/10.1073/pnas.92.20.9363
8. Verschuren EW, Ban KH, Maek MA, Lehman NJ, Jackson PK. Loss of Emi1-dependent APC/C inhibition deregulates E2F target expression and elicits DNA damage-induced senescence. Mol Cell Biol 2007; 27:9795-65; PMID:17875940; http://dx.doi.org/10.1128/MCB.00908-07
9. Barikova J, Rezaei N, Lioitos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence from the perspective. Curr Opin Genet Dev 2011; 21:107-12; PMID:21093253; http://dx.doi.org/10.1016/j.gde.2010.10.005
10. Di Micco R, Fumagalli M, Cicalessa A, Peciccin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42; PMID:17136094; http://dx.doi.org/10.1038/nature05327
11. Betsch K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerdix M, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428:431-7; PMID:15042092; http://dx.doi.org/10.1038/nature02371
12. Mullenders J, Fabius AW, Madiredo M, Bernards R, Beijersbergen RL. A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One 2009; 4:e4798; PMID:19272270; http://dx.doi.org/10.1371/journal.pone.0004798
13. Rowellian E, Mansfield L, Lord CJ, Ashworth A, Jat PS. An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence. BMC Genomics 2011; 12:355; PMID:21740549; http://dx.doi.org/10.1186/1471-2164-12-355
14. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev 2011; 21:107-12; PMID:21093253; http://dx.doi.org/10.1016/j.ogd.2010.10.005
30. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011

31. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10.1038/nature10166

32. Jia M, Soucchelnytski Y, Hellman U, O'Hare M, Jar PS, Soucchelnytski S. Proteome profiling of immortalization-to-senescent transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer. Proteomics Clin Appl 2010; 4:186-28; PMID:21137025; http://dx.doi.org/10.1002/pca.201000006

33. Brummelkamp TR, Bernards R, Agami R. A system for conditional gene expression. BMC Biotechnol 2002; 2:89; PMID:12015983; http://dx.doi.org/10.1186/1472-6750-2-61

34. Davis TL, Walker JR, Loppnau P, Butler-Cole C, Allali-Hassani A, Dhe-Panafax S. Autoregulation by the juxtamembrane region of the human ephrin receptor tyrosine kinase A3 (EphA3). Structure 2008; 16:873-84; PMID:18547520; http://dx.doi.org/10.1016/j.str.2008.03.008

35. Nievergall E, Janes PW, Stemgayer C, Vull M, Haj FG, Teng, SW, et al. PTIP1 regulates Eph receptor function and trafficking. J Cell Biol 2010; 191:1189-203; PMID:21135139; http://dx.doi.org/10.1083/jcb.201005635

36. Chen Z, Wang K, Walvo Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012; 483:613-7; PMID:22425996; http://dx.doi.org/10.1038/nature10957

37. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10.1038/nrc2602

38. Chen Y, Scappo C, Wang X, Fang X, Balgley B, Bolden JE, et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev 2011; 25:2125-36; PMID:21979375; http://dx.doi.org/10.1101/gad.172767.111

39. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46; PMID:12015983; http://dx.doi.org/10.1016/S0092-8674(02)00734-1

40. Alnemri E, Kaufmann S, Kaminaz K. Emerging role of NF-kappaB inhibition in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012; 24:835-45; PMID:22182567; http://dx.doi.org/10.1016/j.cellsig.2011.12.006

41. Guerra C, Collado M, Navas C, Schuhmacher AJ, Guerra C, Collado M, Navas C, Schuhmacher AJ. Copy number variations of EphA3 are associated with multi-plexed processes of hematologic malignancies. Clin Lymphoma Myeloma Leuk 2011; 11:50-3; PMID:21454190; http://dx.doi.org/10.1016/j.clml.2011.09.006

42. Miao H, Nickel CH, Cantley LG, Brugmann LA, Bernardo LN, Wang B, EphA3 kinase activation regulates HGF-induced epithelial branching morphogenesis. J Cell Biol 2003; 162:1281-92; PMID:14547207; http://dx.doi.org/10.1083/jcb.2003064018

43. Vaidya A, Pnain A, Lemke G, Brown A. EphA3 null mutants do not demonstrate motor axon guidance defects. Mol Cell Biol 2003; 23:8902-8; PMID:14545969; http://dx.doi.org/10.1128/MCB.23.22.8902-8908.2003

44. Stephen LJ, Fawkes AL, Verhoeve A, Lemke G, Brown A. A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol 2007; 302:66-79; PMID:17046737; http://dx.doi.org/10.1016/j.ydbio.2006.08.058

45. Gray DC, Hoeffl KP, Peng L, Gu Z, Gogineni A, Murray LJ, et al. pHUSH: a single vector system for conditional gene expression. BMC Biotechnol 2007; 7:61; http://dx.doi.org/10.1186/1472-6750-7-61

46. Brummelkamp TR, Bernardi R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:505-3; PMID:11910072; http://dx.doi.org/10.1126/science.1068999

47. Haverty PM, genoQuest: Provides classes similar to ExpressionSet for copy number analysis. R package version 1.2.0. http://www.biocoductor.org, 2011